Murthy Vasantmeghna S, Mangot Ajish G
Department of Psychiatry, Krishna Institute of Medical Sciences Deemed University, Karad, Satara, Maharashtra, India.
Indian J Pharmacol. 2015 Nov-Dec;47(6):594-9. doi: 10.4103/0253-7613.169593.
Phosphodiesterases (PDE) are exciting new targets in medical sciences. These enzymes are some of the key mediators of cellular functions in the body and hence are attractive sites for drug-induced modulations. With the finding that Tofisopam, a new anxiolytic, inhibits PDEs, the authors were inspired to look into the role of PDE and drugs acting on them in psychiatry. Hence, the review was undertaken. We found several research materials available highlighting the role of PDE in cellular functions and the possible newer etiological mechanisms of neuropsychiatric illnesses such as schizophrenia, depression/anxiety disorders, and cognitive dysfunction involving PDEs. We also found that there are many molecules acting on PDEs, which have the potential to alter the way we treat mental illnesses today. This article is intended to provide an in-depth look at these enzymes so that more cost-effective therapeutic molecules may be synthesized and marketed in India for managing mental illnesses.
磷酸二酯酶(PDE)是医学领域令人兴奋的新靶点。这些酶是身体细胞功能的一些关键介质,因此是药物诱导调节的有吸引力的作用位点。随着新型抗焦虑药托非索泮可抑制磷酸二酯酶这一发现,作者们受到启发,开始研究磷酸二酯酶及其作用药物在精神病学中的作用。因此,进行了本综述。我们发现了几篇研究材料,突出了磷酸二酯酶在细胞功能中的作用,以及诸如精神分裂症、抑郁/焦虑症和涉及磷酸二酯酶的认知功能障碍等神经精神疾病可能的新病因机制。我们还发现有许多作用于磷酸二酯酶的分子,它们有可能改变我们如今治疗精神疾病的方式。本文旨在深入探讨这些酶,以便在印度能够合成并销售更具成本效益的治疗分子来治疗精神疾病。